Literature DB >> 20350361

Effect of neurotrophin-3 genetically modified olfactory ensheathing cells transplantation on spinal cord injury.

Yu-Hai Ma1, Yong Zhang, Li Cao, Jia-Can Su, Zhi-Wei Wang, A-Bing Xu, Shao-Cheng Zhang.   

Abstract

Transplantation of olfactory ensheathing cells (OECs) has emerged as a very promising therapy for spinal cord injury (SCI). Also, local delivery of NT-3 can counteract pathological events and induce a regenerative response after SCI. Supplement of exogenetic NT-3 might be a new approach to SCI repair. In this study, we examined the therapeutic effect of rat NT-3 gene-modified OECs transplantation on SCI. Rat NT-3 gene was transfected into OECs using a retroviral system. The engineered NT-3-OECs were tested for their ability to express and secrete biologically active NT-3 in vitro. Then NT-3-OECs were implanted into contused T9 spinal cord of the adult rats. Their ability of survival and NT-3 production was examined. The effect of axon regeneration was evaluated at the morphological level and promotion of locomotor functional recovery were assessed. The result showed that genetically modified OECs were capable of surviving and producing NT-3 in vivo to significantly improve the recovery after SCI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350361     DOI: 10.3727/096368910X492634

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  19 in total

1.  Schwann cells induce Proliferation and Migration of Oligodendrocyte Precursor Cells Through Secretion of PDGF-AA and FGF-2.

Authors:  Yue-Juan Chen; Jing-Xing Zhang; Lin Shen; Qi Qi; Xiao-Xin Cheng; Zheng-Rong Zhong; Zhi-Quan Jiang; Rui Wang; He-Zuo Lü; Jian-Guo Hu
Journal:  J Mol Neurosci       Date:  2015-06-05       Impact factor: 3.444

2.  Phagocytic removal of neuronal debris by olfactory ensheathing cells enhances neuronal survival and neurite outgrowth via p38MAPK activity.

Authors:  Bao-Rong He; Song-Tao Xie; Ming-Mei Wu; Ding-Jun Hao; Hao Yang
Journal:  Mol Neurobiol       Date:  2013-11-22       Impact factor: 5.590

3.  Early intranasal insulin therapy halts progression of neurodegeneration: progress in Alzheimer's disease therapeutics.

Authors:  Suzanne M de la Monte
Journal:  Aging health       Date:  2012

4.  Activity-dependent increase in neurotrophic factors is associated with an enhanced modulation of spinal reflexes after spinal cord injury.

Authors:  Marie-Pascale Côté; Gregory A Azzam; Michel A Lemay; Victoria Zhukareva; John D Houlé
Journal:  J Neurotrauma       Date:  2011-01-09       Impact factor: 5.269

5.  Neurotrophin-3 Enhances the Effectiveness of Cell Therapy in Chronic Spinal Cord Injuries.

Authors:  O V Stepanova; A D Voronova; A V Chadin; G A Fursa; E K Karsuntseva; M P Valikhov; A S Semkina; I V Reshetov; V P Chekhonin
Journal:  Bull Exp Biol Med       Date:  2022-05-27       Impact factor: 0.804

6.  Clinical and experimental advances in regeneration of spinal cord injury.

Authors:  Jung Keun Hyun; Hae-Won Kim
Journal:  J Tissue Eng       Date:  2010-11-02       Impact factor: 7.813

7.  Long-term survival, axonal growth-promotion, and myelination of Schwann cells grafted into contused spinal cord in adult rats.

Authors:  Xiaofei Wang; Xiao-Ming Xu
Journal:  Exp Neurol       Date:  2014-05-27       Impact factor: 5.330

Review 8.  Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

Review 9.  Cell transplantation for spinal cord injury: a systematic review.

Authors:  Jun Li; Guilherme Lepski
Journal:  Biomed Res Int       Date:  2013-01-15       Impact factor: 3.411

10.  Transplantation of D15A-expressing glial-restricted-precursor-derived astrocytes improves anatomical and locomotor recovery after spinal cord injury.

Authors:  Chunling Fan; Yiyan Zheng; Xiaoxin Cheng; Xiangbei Qi; Ping Bu; Xuegang Luo; Dong H Kim; Qilin Cao
Journal:  Int J Biol Sci       Date:  2012-12-22       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.